Photodynamic therapy as adjunctive therapy for morpheaform basal cell carcinoma

Acta Dermatovenerol Alp Pannonica Adriat. 2011;20(1):23-5.

Abstract

The authors decided to evaluate the possible use of methyl-aminolevulinate photodynamic therapy (MAL-PDT) as adjunctive therapy for morpheaform basal cell carcinoma prior to standard surgical excision in order to reduce tumor size and volume and to facilitate surgical treatment. It was observed that MAL-PDT may be an option as an adjunctive therapy prior to standard surgical excision of morpheaform basal cell carcinoma, leading to less invasive surgery.

MeSH terms

  • Aminolevulinic Acid / analogs & derivatives
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / surgery
  • Chemotherapy, Adjuvant
  • Chromosomes, Artificial, Bacterial
  • Facial Neoplasms / drug therapy
  • Facial Neoplasms / surgery
  • Humans
  • Photosensitizing Agents / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / surgery

Substances

  • Photosensitizing Agents
  • methyl 5-aminolevulinate
  • Aminolevulinic Acid